Top of the morning to you, and a fine one it is. Relatively mild temperatures and clearing skies this morning are livening the Pharmalot campus, where things have quieted down now that our short people have departed for their endeavors. This leaves us to our own devices, notably the coffee kettle, which we are firing up again to enjoy some cups of stimulation. Our choice today is pecan pie. Feel free to choose something equally provocative and join us. Meanwhile, here are some tidbits. Hope your journey today is a smooth one and, as always, do keep in touch …

And then there were five — pharma execs, that is, who have agreed to appear at a Senate Finance Committee hearing later this month to discuss drug prices. Among them: Merck (MRK), Pfizer (PFE), Sanofi (SNY), Bristol-Myers Squibb (BMY), and the Janssen unit of Johnson & Johnson (JNJ). Their scheduled appearances will follow an upbraiding from Sen. Chuck Grassley (R-Iowa), who chairs the committee, and Sen. Ron Wyden (D-Ore.), who chastised the executives for failing to testify at a recent hearing on the subject.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy